Human disease resulting from gene mutations that interfere with appropriate nuclear factor-kappaB activation.
about
Unbalanced Immune System: Immunodeficiencies and AutoimmunityUpdate on the hyper immunoglobulin M syndromesPersistent systemic inflammation and atypical enterocolitis in patients with NEMO syndrome.NF-kappaB-dependent induction of cathelicidin-related antimicrobial peptide in murine mast cells by lipopolysaccharideToll-like receptor 7 and 9 defects in common variable immunodeficiency.Cell penetrating peptide inhibitors of nuclear factor-kappa B.IKBKG (nuclear factor-kappa B essential modulator) mutation can be associated with opportunistic infection without impairing Toll-like receptor function.Molecular immunity to mycobacteria: knowledge from the mutation and phenotype spectrum analysis of Mendelian susceptibility to mycobacterial diseases.Involvement of and interaction between WNT10A and EDA mutations in tooth agenesis cases in the Chinese populationDefective lymphoid organogenesis underlies the immune deficiency caused by a heterozygous S32I mutation in IκBα.Immune deficiency caused by impaired expression of nuclear factor-kappaB essential modifier (NEMO) because of a mutation in the 5' untranslated region of the NEMO geneA disorder-induced domino-like destabilization mechanism governs the folding and functional dynamics of the repeat protein IκBαThe cell biology of cryptosporidium infectionInfectious diseases in patients with IRAK-4, MyD88, NEMO, or IκBα deficiency.NEMO is a key component of NF-κB- and IRF-3-dependent TLR3-mediated immunity to herpes simplex virus.Opposing roles of NF-kappaB family members in the regulation of NK cell proliferation and production of IFN-gamma.Immune microenvironment as a factor of breast cancer progression.Hypohidrotic ectodermal dysplasia and immunodeficiency with coincident NEMO and EDA mutations.Haploinsufficiency of the NF-κB1 Subunit p50 in Common Variable Immunodeficiency.The NF-kappaB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease.Recruitment of A20 by the C-terminal domain of NEMO suppresses NF-κB activation and autoinflammatory disease.Hypomorphic nuclear factor-kappaB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity.The zinc finger domain of IKKγ (NEMO) protein in health and diseaseToll-like receptors' pathway disturbances are associated with increased susceptibility to infections in humans.Long-term and acute effects of gliadin on small intestine of patients on potentially pathogenic networks in celiac disease.Kruppel-like factor 2 is a transcriptional regulator of chronic and acute inflammation.Normal human CD4(+) helper T cells express Kv1.1 voltage-gated K(+) channels, and selective Kv1.1 block in T cells induces by itself robust TNFα production and secretion and activation of the NFκB non-canonical pathway.Development of a clinical assay to evaluate toll-like receptor function.HIV-1 Nef inhibits lipopolysaccharide-induced IL-12p40 expression by inhibiting JNK-activated NFkappaB in human monocytic cells.A novel gain-of-function IKBA mutation underlies ectodermal dysplasia with immunodeficiency and polyendocrinopathy.Dental and oral anomalies in incontinentia pigmenti: a systematic review.A red baby should not be taken too lightly.Challenges in the use of allogeneic hematopoietic SCT for ectodermal dysplasia with immune deficiency.Functional polymorphism of theNFKB1gene promoter is not relevant in predisposition to celiac diseaseΩ-3 fatty acids-supplementary in gestation alleviates neuroinflammation and modulates neurochemistry in rats
P2860
Q28075911-CE0DDB30-ADA7-45DC-91EB-0F6322C3E0F2Q28972255-4EC67F3A-C9F2-4C76-A29E-4C18C3BE5285Q33567536-92F7A798-9BB2-4A74-AE1F-767515F2941EQ33621811-C64D1DDA-B7A4-4D0B-9C56-A1E8B1411B65Q34013669-36DCF6F9-6FD4-485D-A0CA-12F10AB6D242Q34289086-C7594657-9925-4A34-8403-BFD93D333C73Q34630390-ECFBD20E-D983-43B1-8858-9046E5553184Q34809934-BB8E3FAB-26FC-494F-9EC0-83EED927C8A7Q35060281-748BB355-5AF0-4840-8304-3159F0E45937Q35064876-0849E0F0-8268-46C1-B00D-72D136C5EB4CQ35072760-0197719F-23FC-46A3-81FD-BA5B179B1F31Q35075087-0ACC1C6D-52DB-4F80-BC1A-C726250EA8F4Q35089632-288431A5-5FF2-4C39-BAD2-1836182F0B5DQ35090141-ECC3AC37-8A1E-4652-B370-942D34F9784AQ35190204-05E2A641-B711-4870-96B9-74CD169F56D7Q35641142-E1CFCB9A-0F18-4F9A-91A2-9E29AE7A913CQ35780464-F63E6F8F-0A82-4890-9819-DA3E6F22E94CQ35927447-3114EFE0-20B3-4D16-9B54-941A8BAB0FF3Q36045102-95862520-FD04-4D3F-B988-769B896C90CAQ36386035-79AD6D32-3E84-4B53-949C-CDAAC52E2A24Q36598807-C21C1CCF-054F-40FE-9827-19247BFA5052Q37262549-57E4E359-7356-437C-9B9C-6FD3D7A039E5Q37295365-603CA52D-A9A7-4EBB-9E2F-D427453A3332Q38140711-3D787846-C2D4-4653-8904-F3160C828AC1Q38508755-9F4643D2-7BD8-4288-92A8-551F4A5C2BDBQ39180450-4986D588-438D-48DA-BADC-C28D831183B5Q40892979-7ABA8047-01C4-419A-9485-38CEBEA1465DQ41968997-B82A5B2A-12F2-412C-BFBD-4D308A2D0DF7Q42084744-3F3CA072-FA19-48E8-9108-82AA93C94041Q45345436-D6C3EF7B-8888-4919-B4FC-EC01D52DAC01Q47976138-6B9B6A44-6D1C-4226-855A-D8C022BFD37AQ50504283-B123FA1D-9F53-4023-9078-D7AC2E7BDC69Q53453725-C70F39C0-7B0F-456F-A3D5-77A13CB8828BQ57307128-D31E217A-08A6-4BD8-ABDF-217C508CF3C2Q58614498-2A3162DB-3FB2-4FFF-BBBE-3A5E2E949F96
P2860
Human disease resulting from gene mutations that interfere with appropriate nuclear factor-kappaB activation.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Human disease resulting from g ...... lear factor-kappaB activation.
@ast
Human disease resulting from g ...... lear factor-kappaB activation.
@en
type
label
Human disease resulting from g ...... lear factor-kappaB activation.
@ast
Human disease resulting from g ...... lear factor-kappaB activation.
@en
prefLabel
Human disease resulting from g ...... lear factor-kappaB activation.
@ast
Human disease resulting from g ...... lear factor-kappaB activation.
@en
P2860
P1476
Human disease resulting from g ...... lear factor-kappaB activation.
@en
P2093
Raif S Geha
P2860
P356
10.1111/J.0105-2896.2005.00221.X
P577
2005-02-01T00:00:00Z